摘要
Objective:The aims of this study were to evaluate potential side effects of 18F-fluoroerythronitroimidazole (18F-FETNIM) as a new-type hypoxia-imaging agent and to investigate the feasibility of 18F-FETNIM PET imaging in advanced non-small cell lung cancer (NSCLC) patients and the correlations of hypoxia extent with tumor volume or pathological type. Methods: Twenty-six NSCLC patients were prospectively included in the study. PET/CT scans were performed 2 h after intravenous injection of 18F-FETNIM in all 26 patients. A pixel-by-pixel calculation of tumor to blood (T/B) activity ratio for all image planes was calculated. The number of pixels in the tumor volume with a T/B ratio≥ 1.5,indicating significant hypoxia,was determined and converted to mL units to measure the hypoxia volume (HV). Results: The images were clearly identified after 2 h post-injection of 18F-FETNIM. The tumors in 4 cases were not distinguished from background,while the remaining 22 displayed local 18F-FETNIM uptake in thoracic lesions moderately to markedly higher than background. There was no correlation between 18F-FETNIM uptake with pathological type. There were significant correlations of HV and also the T/B ratio with tumor volume. Conclusion:18F-FETNIM is a promising hypoxia-imaging agent which clinical use is safe and satisfactory. The preliminary study provides valuable methods and experience to its further research.
Objective： The aims of this study were to evaluate potential side effects of ^18F-fluoroerythronitroimidazole （^18F- FETNIM） as a new-type hypoxia-imaging agent and to investigate the feasibility of ^18F-FETNIM PET imaging in advanced non-small cell lung cancer （NSCLC） patients and the correlations of hypoxia extent with tumor volume or pathological type. Methods： Twenty-six NSCLC patients were prospectively included in the study. PET/CT scans were performed 2 h after intravenous injection of ^18F-FETNIM in all 26 patients. A pixel-by-pixel calculation of tumor to blood （T/B） activity ratio for all image planes was calculated. The number of pixels in the tumor volume with a T/B ratio ≥ 1.5, indicating significant hypoxia, was determined and converted to mL units to measure the hypoxia volume （HV）. Results： The images were clearly identified after 2 h post-injection of ^18F-FETNIM. The tumors in 4 cases were not distinguished from background, while the remaining 22 displayed local ^18F-FETNIM uptake in thoracic lesions moderately to markedly higher than background. There was no correla- tion between ^18F-FETNIM uptake with pathological type. There were significant correlations of HV and also the T/B ratio with tumor volume. Conclusion： ^18F-FETNIM is a promising hypoxia-imaging agent which clinical use is safe and satisfactory. The preliminary study provides valuable methods and experience to its further research.
关键词
非小细胞肺癌
CT扫描
显像剂
PET
缺氧
临床观察
静脉注射
临床使用
^18F-fluoroerythronitroimidazole （^18F-FETNIM）
hypoxia
imaging
positron emission tomography （PET）
non- small cell lung cancer （NSCLC）
